PT  - JOURNAL ARTICLE
AU  - Peter Horby
AU  - Marion Mafham
AU  - Louise Linsell
AU  - Jennifer L Bell
AU  - Natalie Staplin
AU  - Jonathan R Emberson
AU  - Martin Wiselka
AU  - Andrew Ustianowski
AU  - Einas Elmahi
AU  - Benjamin Prudon
AU  - Anthony Whitehouse
AU  - Timothy Felton
AU  - John Williams
AU  - Jakki Faccenda
AU  - Jonathan Underwood
AU  - J Kenneth Baillie
AU  - Lucy Chappell
AU  - Saul N Faust
AU  - Thomas Jaki
AU  - Katie Jeffery
AU  - Wei Shen Lim
AU  - Alan Montgomery
AU  - Kathryn Rowan
AU  - Joel Tarning
AU  - James A Watson
AU  - Nicholas J White
AU  - Edmund Juszczak
AU  - Richard Haynes
AU  - Martin J Landray
TI  - Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial
AID  - 10.1101/2020.07.15.20151852
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.15.20151852
4099  - http://medrxiv.org/content/early/2020/07/15/2020.07.15.20151852.short
4100  - http://medrxiv.org/content/early/2020/07/15/2020.07.15.20151852.full
AB  - Background Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (COVID-19) on the basis of in vitro activity, uncontrolled data, and small randomized studies.Methods The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is a randomized, controlled, open-label, platform trial comparing a range of possible treatments with usual care in patients hospitalized with COVID-19. We report the preliminary results for the comparison of hydroxychloroquine vs. usual care alone. The primary outcome was 28-day mortality.Results 1561 patients randomly allocated to receive hydroxychloroquine were compared with 3155 patients concurrently allocated to usual care. Overall, 418 (26.8%) patients allocated hydroxychloroquine and 788 (25.0%) patients allocated usual care died within 28 days (rate ratio 1.09; 95% confidence interval [CI] 0.96 to 1.23; P=0.18). Consistent results were seen in all pre-specified subgroups of patients. Patients allocated to hydroxychloroquine were less likely to be discharged from hospital alive within 28 days (60.3% vs. 62.8%; rate ratio 0.92; 95% CI 0.85-0.99) and those not on invasive mechanical ventilation at baseline were more likely to reach the composite endpoint of invasive mechanical ventilation or death (29.8% vs. 26.5%; risk ratio 1.12; 95% CI 1.01-1.25). There was no excess of new major cardiac arrhythmia.Conclusions In patients hospitalized with COVID-19, hydroxychloroquine was not associated with reductions in 28-day mortality but was associated with an increased length of hospital stay and increased risk of progressing to invasive mechanical ventilation or death.Funding Medical Research Council and NIHR (Grant ref: MC_PC_19056).Trial registrations The trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04381936Clinical Protocols https://www.recoverytrial.net Funding StatementThe RECOVERY trial is supported by a grant to the University of Oxford from UK Research and Innovation/National Institute for Health Research (NIHR) (Grant reference: MC_PC_19056) and by core funding provided by NIHR Oxford Biomedical Research Centre, Wellcome, the Bill and Melinda Gates Foundation, the Department for International Development, Health Data Research UK, the Medical Research Council Population Health Research Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit Support Funding. WSL is supported by core funding provided by NIHR Nottingham Biomedical Research Centre. TJ received funding from UK Medical Research Council (MC_UU_0002/14). TJ is supported by a NIHR Senior Research Fellowship (NIHR-SRF-2015-08-001). NJW, JAW and JT are part of the Mahidol Oxford Research Unit supported by the Wellcome Trust. Tocilizumab was provided free of charge for this study by Roche Products Limited. AbbVie contributed some supplies of lopinavir-ritonavir for use in the study. Other medication used in the study was supplied from routine National Health Service stock.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was conducted in accordance with the principles of the International Conference on Harmonization Good Clinical Practice guidelines and approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and the Cambridge East Research Ethics Committee (ref: 20/EE/0101).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe protocol, consent form, statistical analysis plan, definition & derivation of clinical characteristics & outcomes, training materials, regulatory documents, and other relevant study materials are available online at www.recoverytrial.net This is a preliminary report and follow-up is ongoing. Data will be made available to bona fide researchers registered with an appropriate institution within 3 months of the final participant completing 28-day follow-up. As described in the protocol, the trial Steering Committee will facilitate the use of the study data and approval will not be unreasonably withheld. However, the Steering Committee will need to be satisfied that any proposed publication is of high quality, honours the commitments made to the study participants in the consent documentation and ethical approvals, and is compliant with relevant legal and regulatory requirements (e.g. relating to data protection and privacy). The Steering Committee will have the right to review and comment on any draft manuscripts prior to publication. https://www.ndph.ox.ac.uk/data-access https://www.recoverytrial.net